With regards to CEBPA, the presence of biallelic mutations in AML marks a distinct disease entity with a better prognosis compared to patients with single-variant or wild-type CEBPA [9].The genetic profile in fact trumps the presence of morphologic dysplasia and these are still classified as AML with biallelic CEBPA mutations rather than AML with myelodysplasia-related changes in the setting of dyspoiesis [10]. Here, CEBPA is linked to acute myeloid leukemia.